Group 1 - The company reported a revenue of 776,132,021.01 yuan for the first half of 2025, representing a year-on-year growth of 16.57% [2] - The net profit attributable to shareholders of the listed company was 34,706,358.19 yuan, showing a significant year-on-year increase of 109.70% [2]

Company Overview - Shaoxing BSM Chemical Co., Ltd. reported a revenue of CNY 776.13 million for the first half of 2025, representing a 16.57% increase compared to CNY 665.83 million in the same period last year [1] - The net profit attributable to shareholders increased by 109.70% to CNY 34.71 million from CNY 16.55 million year-on-year [1] - Basic and diluted earnings per share both doubled to CNY 0.10 from CNY 0.05 [1] Financial Performance - The company experienced a significant decline in net cash flow from operating activities, which was negative CNY 22.33 million, down 162.44% from CNY 35.76 million in the previous year [1] - The total assets at the end of the reporting period were CNY 3.26 billion, a 3.04% increase from CNY 3.16 billion at the end of the previous year [2] - The net assets attributable to shareholders rose to CNY 1.73 billion, reflecting a 1.02% increase from CNY 1.71 billion [2] Shareholder Information - The largest shareholder, Ningbo BSM Investment Holdings Co., Ltd., holds 23.02% of the shares, with 41.33 million shares pledged [3] - Other significant shareholders include Jiangsu Xihua Private Equity Fund Management Co., Ltd. with 5.35% and Wang Qifeng with 3.38% [3] - The report indicates that there were no changes in the controlling shareholder or actual controller during the reporting period [4]

Group 1 - The board meeting of Shaoxing Baismei Chemical Co., Ltd. was held on August 18, 2025, with all 8 directors present, confirming compliance with legal and regulatory requirements [1] - The board approved the 2025 semi-annual report, affirming that it accurately reflects the company's operational status without any misleading statements or omissions [1][2] - The company has adhered to regulations regarding the storage and use of raised funds, ensuring no violations occurred in the management of these funds [2][3] Group 2 - The board approved the extension of the fundraising project timeline, which does not alter the project's implementation, funding purposes, or investment scale, and will not adversely affect the company's operations [3]

Group 1 - The sixth meeting of the fourth supervisory board of Shaoxing Baisimei Chemical Co., Ltd. was held on August 18, 2025, with all six supervisors present, confirming compliance with legal and regulatory requirements [1] - The supervisory board approved the 2025 semi-annual report, stating that it accurately reflects the company's actual situation without any false records or misleading statements [1][2] - The company strictly adhered to relevant regulations regarding the storage and use of raised funds, with all procedures followed correctly, and no violations reported [2] Group 2 - The company decided to postpone some fundraising investment projects based on the usage progress of raised funds and actual operating conditions, ensuring no change in the purpose of the funds or harm to shareholder interests [3] - The postponement of investment projects does not involve related transactions and complies with relevant laws and regulations [3]

证券代码：300796 证券简称：贝斯美 公告编号：2025-065 绍兴贝斯美化工股份有限公司（以下简称"公司"）于2025年8月18日召开了第四 届董事会第九次会议、第四届监事会第六次会议，分别审议通过了《关于公司部分 募投项目延期的议案》，同意公司在募投项目实施主体、实施方式、建设内容、募 集资金投资用途及投资规模不发生变更的前提下，对首发部分募投项目达到预定可 使用状态的时间进行调整，该议案无需提交公司股东大会审议。现将具体情况公告 如下： 一、首发募集资金的基本情况 经中国证券监督管理委员会证监发行字[2019]1783号文核准，公司于2019年11月 向社会公开发行人民币普通股（A股）3,030万股，每股发行价为14.25元，应募集资 金总额为人民币43,177.50万元，根据有关规定扣除发行费用3,879.74万元后，实际募 集资金净额为39,297.76万元。该募集资金已于2019年11月到账。上述资金到账情况 业经容诚会计师事务所会验字[2019]7999号《验资报告》验证。公司对募集资金采 取了专户存储管理。 绍兴贝斯美化工股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、 ...

根据《深圳证券交易所上市公司自律监管指引第2号—创业板上市公司规范运作》 《深圳证券交易所创业板上市公司自律监管指南第1号—业务办理》《企业会计准则》以 及公司关于会计政策的相关规定，绍兴贝斯美化工股份有限公司（以下简称"公司 "） 为真实、准确、客观反映公司的财务状况和经营成果，根据《企业会计准则》相关规定， 本着谨慎性原则，对合并财务报表范围内的各项需要计提减值的资产进行了评估和分析， 对预计可能发生减值损失的相关资产计提减值准备。根据《深圳证券交易所上市公司自 律监管指引第2号—创业板上市公司规范运作》等法律法规的规定，本次计提减值准备无 需提交董事会或股东大会审议，现将具体情况公告如下： 一、本次计提减值准备的情况 （一）本次计提减值准备的原因 证券代码：300796 证券简称：贝斯美 公告编号：2025-064 绍兴贝斯美化工股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或者重大遗漏。 （三）计提资产减值准备的具体说明 根据《企业会计准则第22号金融工具确认和计量》 以及公司会计政策，公 司应收款项、其他应收款以预期信用损失为基础确认信用减值损失， ...

Group 1 - The report details the non-operating fund occupation and related transactions of Shaoxing Baisimei Chemical Co., Ltd. for the first half of 2025, including amounts and reasons for fund occupation [1] - The total non-operating fund occupation at the end of June 2025 amounts to 323,363,046.32 yuan, with significant contributions from related parties [1] - The company has recorded a total of 267,369,206.32 yuan in receivables from its subsidiary Tongling Baisimei Technology Co., Ltd. as of June 2025 [1] Group 2 - The report indicates that the company has engaged in non-operating transactions with its subsidiaries, including a loan of 25,000,000 yuan from Tongling Baisimei Technology Co., Ltd. [1] - Another subsidiary, Ningbo Baisimei New Materials Technology Co., Ltd., has a receivable balance of 18,000,000 yuan as of June 2025, reflecting ongoing financial interactions [1] - The report was approved by the board of directors on August 18, 2025, indicating compliance with corporate governance standards [1]

中泰证券股份有限公司 关于绍兴贝斯美化工股份有限公司 首发部分募投项目延期的核查意见 中泰证券股份有限公司（以下简称"保荐机构"）作为绍兴贝斯美化工股份 有限公司（以下简称"公司"）持续督导保荐机构，根据《证券发行上市保荐业 务管理办法》《深圳证券交易所创业板股票上市规则》《上市公司募集资金监管 规则》及《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司 规范运作》等法律法规的规定履行持续督导职责，对公司部分募投项目延期的 事项进行了核查，情况如下： 一、首发募集资金的基本情况 经中国证券监督管理委员会证监发行字[2019]1783 号文核准，公司于 2019 年 11 月向社会公开发行人民币普通股（A 股）3,030 万股，每股发行价为 14.25 元，应募集资金总额为人民币 43,177.50 万元，根据有关规定扣除发行费用 资报告》验证。公司对募集资金采取了专户存储管理。 二、首发募集资金使用与管理情况 截至 2025 年 6 月 30 日，公司首次公开发行股票募集资金投资项目及使用情 况如下： 拟投入金额 金金额 新建企业研发中心技改 项目 2 收购宁波捷力克 80%股 权3 注：1、公 ...

（文章来源：证券日报） 证券日报网讯 8月19日晚间，贝斯美发布公告称，公司第四届监事会第六次会议审议通过了《关于公司 2025年半年度报告全文及摘要的议案》等多项议案。 ...

（文章来源：证券日报） 证券日报网讯 8月19日晚间，贝斯美发布公告称，公司第四届董事会第九次会议审议通过了《关于公司 2025年半年度报告全文及摘要的议案》等多项议案。 ...